The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties

Journal of Lipid Research

Volumn 56, Issue 9, 2015, Pages 1727-1737

  Schwendeman, Anna ^a   Sviridov, Denis O ^c   Yuan, Wenmin ^a   Guo, Yanhong ^b   Morin, Emily E ^a   Yuan, Yue ^a,d   Stonik, John ^c   Freeman, Lita ^c   Ossoli, Alice ^c   Thacker, Seth ^c   Killion, Salena ^e   Pryor, Milton ^c   Chen, Y Eugene ^b   Turner, Scott ^e   Remaley, Alan T ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^e KINEMED INC   (United States)

Author keywords

Apolipoprotein A I; Atherosclerosis; High density lipoprotein; Inflammation; Peptides; Sphingomyelin

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLLEUCYLLYSYLGLUTAMYLALANYLPHENYLALANYLPROLYLASPARTYLTRYPTOPHYLALANYLLYSYLALANYLTYROSYLASPARTYLLYSYLALANYLALANYLGLUTAMYLLYSYLALANYLLYSYLGLUTAMYLALANYLALANINE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGENT; PHOSPHOLIPID DERIVATIVE; PRE BETA HIGH DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR BI; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; 1-PALMITOYL-2-OLEOYLPHOSPHATIDYLCHOLINE; APOLIPOPROTEIN A1; CHOLESTEROL; PEPTIDE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SPHINGOMYELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG FORMULATION; DRUG POTENCY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; ANIMAL; ATHEROSCLEROSIS; GENETICS; HUMAN; INFLAMMATION; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MICE; PEPTIDES; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; RATS; SPHINGOMYELINS;

EID: 84941007431     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M060285     Document Type: Article

References (36)

1. Remaley, A. T., A. Amar, and D. Sviridov. 2008. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev. Cardiovasc. Ther. 6: 1203-1215.
2. Newton, R. S., and B. R. Krause. 2002. HDL therapy for the acute treatment of atherosclerosis. Atheroscler. Suppl. 3: 31-38.
3. Badimon, J. J., L. Badimon, and V. Fuster. 1990. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85: 1234-1241.
4. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schownhagen, M. Yasin, G. M. Eaton, M. A. Laurer, W. S. Sheldon, C. L. Grines, S. Halpern, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300.
5. Tardif, J. C., J. Gregoire, P. L. L'Allier, R. Ibrahim, J. Lespérance, T. H. Heinonen, S. Kouz, C. Berry, R. Basser, M-A. Lavoie, et al. 2007. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 297: 1675-1682.
6. Rye, K. A., N. J. Hime, and P. J. Barter. 1996. The Influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J. Biol. Chem. 271: 4243-4250.
7. Davidson, W. S., K. L. Gillotte, S. Lund-Katz, W. J. Johnson, G. H. Rothblat, and M. C. Phillips. 1995. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol. J. Biol. Chem. 270: 5882-5890.
8. Marmillot, P., S. Patel, and M. R. Lakshman. 2007. Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high-density lipoproteins. Metabolism. 56: 251-259.
9. Ma, C. I., J. A. Beckstead, A. Thompson, A. Hafiane, R. H. Wang, R. O. Ryan, and R. S. Kiss. 2012. Tweaking the cholesterol efflux capacity of reconstituted HDL. Biochem. Cell Biol. 90: 636-645.
10. Sparks, D. L., W. S. Davidson, S. Lund-Katz, and M. C. Phillips. 1995. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein AI structure and particle stability. J. Biol. Chem. 270: 26910-26917.
11. Parks, J. S., K. W. Huggins, A. K. Gebre, and E. R. Burleson. 2000. Phosphatidylcholine fluidity and structure affect lecithin:cholesterol acyltransferase activity. J. Lipid Res. 41: 546-553.
12. Kontush, A., M. Lhomme, and M. J. Chapman. 2013. Unravelling the complexities of the HDL lipidome. J. Lipid Res. 54: 2950-2963.
13. Camont, L., M. Lhomme, F. Rached, W. Le Goff, A. Nègre-Salvayre, R. Salvayre, C. Calzada, M. Lagarde, M. J. Chapman, and A. Kontush. 2013. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33: 2715-2723.
14. Kontush, A., P. Therond, A. Zerrad, M. Couturier, A. Négre-Salvayre, J. A. de Souza, S. Chantepie, and M. J. Chapman. 2007. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 27: 1843-1849.
15. Eriksson, M., L. A. Carlson, T. A. Miettinen, and B. Angelin. 1999. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 100: 594-598.
16. Nanjee, M. N., J. E. Doran, P. G. Lerch, and N. E. Miller. 1999. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 19: 979-989.
17. Marchesi, M., E. A. Booth, T. Davis, C. L. Bisgaier, and B. R. Lucchesi. 2004. Apolipoprotein A-I-Milano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J. Pharmacol. Exp. Ther. 311: 1023-1031.
18. Hippalgaonkar, K., S. Majumdar, and V. Kansara. 2010. Injectable lipid emulsions - advancements, opportunities and challenges. AAPS PharmSciTech. 11: 1526-1540.
19. Di Bartolo, B. A., S. J. Nicholls, S. Bao, K. A. Rye, A. K. Heather, P. J. Barter, and C. Bursill. 2011. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis. 217: 395-400.
20. Tardy, C., M. Goffinet, N. Boubekeur, R. Ackermann, G. Sy, A. Bluteau, G. Cholez, C. Keyserling, N. Lalwani, J. F. Paolini, et al. 2014. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 232: 110-118.
21. Ohvo-Rekilä, H., B. Ramstedt, P. Leppimäki, and J. P. Slotte. 2002. Cholesterol interactions with phospholipids in membranes. Prog. Lipid Res. 41: 66-97.
22. Ramstedt, B., and J. P. Slotte. 1999. Interaction of cholesterol with sphingomyelins and acyl-chain-matched phosphatidylcholines: A comparative study of the effect of the chain length. Biophys. J. 76: 908-915.
23. Silva, L. C., A. H. Futerman, and M. Prieto. 2009. Lipid raft composition modulates sphingomyelinase activity and ceramide-induced membrane physical alterations. Biophys. J. 96: 3210-3222.
24. Dasseux, J-L., T. J. Rea, and A. A. Shenderova, inventors. 2003. Method of treating dyslipidemic disorder. United States patent US 7994120 B2.
25. Sethi, A. A., J. A. Stonik, F. Thomas, S. J. Demosky, M. Amar, E. Neufeld, H. B. Brewer, W. S. Davidson, W. D'Souza, D. Sviridov, et al. 2008. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J. Biol. Chem. 283: 32273-32282.
26. Amar, M. J. A., W. D'Souza, S. Turner, S. Demosky, D. Sviridov, J. Stonik, J. Luchoomun, J. Voogt, M. Hellerstein, D. Sviridov, et al. 2010. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J. Pharmacol. Exp. Ther. 334: 634-641.
27. Tabet, F., A. T. Remaley, A. I. Segaliny, J. Millet, L. Yan, S. Nakhla, P. J. Barter, K. A. Rye, and G. Lambert. 2010. The 5A apolipoprotein A-I mimetic peptide displays anti-inflammatory and antioxidant properties in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol. 30: 246-252.
28. Freeman, L. A. 2013. Native-native 2D gel electrophoresis for HDL subpopulation analysis. Methods Mol. Biol. 1027: 353-367.
29. Freeman, L. A. 2013. Western blots. Methods Mol. Biol. 1027: 369-385.
30. Asztalos, B. F., M. Tani, and E. J. Schaefer. 2011. Metabolic and functional relevance of HDL subspecies. Curr. Opin. Lipidol. 22: 176-185.
31. Yancey, P. G., A. E. Bortnick, G. Kellner-Weibel, M. de la Llere-Moya, M. Phillips, and G. H. Rothblat. 2003. Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 23: 712-719.
32. Williams, K. J., R. Scalia, K. D. Mazany, W. V. Rodrigueza, and A. M. Lefer. 2000. Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport. Arterioscler. Thromb. Vasc. Biol. 20: 1033-1039.
33. Rodrigueza, W. V., K. D. Mazany, A. D. Essenburg, M. E. Pape, T. J. Rea, C. L. Bisgaier, and K. J. Williams. 1997. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17: 2132-2139.
34. Mineo, C., H. Deguchi, J. H. Griffin, and P. W. Shaul. 2006. Endothelial and antithrombotic actions of HDL. Circ. Res. 98: 1352-1364.
35. Zhu, X., J. Y. Lee, J. M. Timmins, J. M. Brown, E. Boudyguina, A. Mulya, A. K. Gebre, M. C. Willingham, E. M. Hiltbold, N. Mishra, et al. 2008. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J. Biol. Chem. 283: 22930-22941.
36. De Nardo, D., L. I. Labzin, H. Kono, R. Seki, S. V. Schmidt, M. Beyer, D. Xu, S. Zimmer, C. Lahrmann, F. A. Schildberg, et al. 2014. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat. Immunol. 15: 152-160.